The incidence and prevalence of hepatitis E virus (HEV) infection has increased in many developed countries over the last decade. It has also been recognised that HEV infection can persist in immunosuppressed individuals, leading if left untreated to chronic hepatitis and significant liver fibrosis. Transplant recipients are therefore at risk of developing persistent HEV infection. There are currently no international guidelines on the management of hepatitis E in transplant recipients. These guidelines have therefore been developed to inform clinical teams and patients about hepatitis E, to help increase the recognition of persistent hepatitis E infection, and to provide clear guidance on its management.
Read full guideline